Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fangfang Lai

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
European Journal of Medicinal Chemistry|June 20, 2021
Identification of 3, 4-disubstituted pyridine derivatives as novel CDK8 inhibitorsHaochao Zhang, Liandong Jing, Man Liu, et al.
European Journal of Medicinal Chemistry|December 4, 2023
Rational design and optimization of novel 4-methyl quinazoline derivatives as PI3K/HDAC dual inhibitors with benzamide as zinc binding moiety for the treatment of acute myeloid leukemiaKehui Zhang, Rui Huang, Ming Ji, et al.
Acta Pharmaceutica Sinica. B|February 22, 2020
A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal modelsJing Jin, Nina Xue, Yuan Liu, et al.
Journal of Medicinal Chemistry|September 12, 2023
Exploration and Biological Evaluation of 1,3-Diamino-7<i>H</i>-pyrrol[3,2-<i>f</i>]quinazoline Derivatives as Dihydrofolate Reductase InhibitorsZihao Zhu, Cantong Chen, Jie Zhang, et al.
Journal of Medicinal Chemistry|May 24, 2019
Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone DeacetylasesKehui Zhang, Fangfang Lai, Songwen Lin, et al.
Acta Pharmaceutica Sinica. B|March 27, 2023
S1PR1 serves as a viable drug target against pulmonary fibrosis by increasing the integrity of the endothelial barrier of the lungMengyao Hao, Rong Fu, Jun Tai, et al.
Journal of Lipid Research|June 9, 2014
Rutaecarpine suppresses atherosclerosis in ApoE-/- mice through upregulating ABCA1 and SR-BI within RCTYanni Xu, Qi Liu, Yang Xu, et al.
Acta Pharmaceutica Sinica. B|December 4, 2023
Discovery and druggability evaluation of pyrrolamide-type GyrB/ParE inhibitor against drug-resistant bacterial infectionXintong Zhao, Jing Feng, Jie Zhang, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
European Journal of Medicinal Chemistry|June 20, 2021
Identification of 3, 4-disubstituted pyridine derivatives as novel CDK8 inhibitorsHaochao Zhang, Liandong Jing, Man Liu, et al.
European Journal of Medicinal Chemistry|December 4, 2023
Rational design and optimization of novel 4-methyl quinazoline derivatives as PI3K/HDAC dual inhibitors with benzamide as zinc binding moiety for the treatment of acute myeloid leukemiaKehui Zhang, Rui Huang, Ming Ji, et al.
Acta Pharmaceutica Sinica. B|February 22, 2020
A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal modelsJing Jin, Nina Xue, Yuan Liu, et al.
Journal of Medicinal Chemistry|September 12, 2023
Exploration and Biological Evaluation of 1,3-Diamino-7<i>H</i>-pyrrol[3,2-<i>f</i>]quinazoline Derivatives as Dihydrofolate Reductase InhibitorsZihao Zhu, Cantong Chen, Jie Zhang, et al.
Journal of Medicinal Chemistry|May 24, 2019
Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone DeacetylasesKehui Zhang, Fangfang Lai, Songwen Lin, et al.
Acta Pharmaceutica Sinica. B|March 27, 2023
S1PR1 serves as a viable drug target against pulmonary fibrosis by increasing the integrity of the endothelial barrier of the lungMengyao Hao, Rong Fu, Jun Tai, et al.
Journal of Lipid Research|June 9, 2014
Rutaecarpine suppresses atherosclerosis in ApoE-/- mice through upregulating ABCA1 and SR-BI within RCTYanni Xu, Qi Liu, Yang Xu, et al.
Acta Pharmaceutica Sinica. B|December 4, 2023
Discovery and druggability evaluation of pyrrolamide-type GyrB/ParE inhibitor against drug-resistant bacterial infectionXintong Zhao, Jing Feng, Jie Zhang, et al.
Pageof 7